false
0001367083
0001367083
2025-09-29
2025-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported) September 29,
2025
SONOMA
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-33216 |
|
68-0423298 |
| (State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
| of incorporation) |
|
File Number) |
|
Identification No.) |
5445
Conestoga Court, Suite
150
Boulder, CO 80301
(Address of principal executive offices)
(Zip Code)
(800) 759-9305
(Registrant’s telephone number, including
area code)
Not applicable.
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
| Common
Stock |
SNOA |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Attached is the updated investor
presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto
as Exhibit 99.1.
Except for historical information
herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance
of the Company.
These forward-looking statements
are identified by the use of words such as “will,” “develop,” “project,” “expect,” and
“expand,” among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent
in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments
may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals,
clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as
large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient
to meet the Company’s cash needs, fund further development, as well as uncertainties relative to fluctuations in foreign currency
exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude
of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time
in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking
statements, except as required by law.
| Item 9.01 | Financial
Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number |
|
Description |
| 99.1 |
|
Investor Presentation as of September 29, 2025. |
| 104 |
|
Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). |
___________________
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
SONOMA PHARMACEUTICALS, INC. |
| |
|
| |
|
| Date: September 29, 2025 |
By: |
/s/ Amy Trombly |
| |
Name:
Title: |
Amy Trombly
Chief Executive Officer |
